Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin

Cyrkowicz, A

doi:10.1016/s0301-2115(01)00482-1

Cited by 10 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are similar to those for clinical DVT and non-fatal PE reported previously [2,28]. Prophylaxis with LMWH after surgery causes significant reductions in the incidence rates of DVT and fatal PE [29], and the incidence of VTE in the treatment group in our study was zero.…”

Section: Discussionsupporting

confidence: 92%

Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial

Alalaf

Jawad

et al. 2015

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

To cite this article: Alalaf SK, Jawad AK, Jawad RK, Ali MS, Al Tawil NG. Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial. J Thromb Haemost 2015; 13: 2161-7.Summary. Background: Venous thromboembolism (VTE) is the leading cause of mortality and morbidity in women following gynecologic surgery. Objectives: To determine the efficacy of a second-generation low molecular weight heparin (bemiparin) for thromboprophylaxis after benign gynecologic surgery. Methods: We performed a singleblind randomized controlled trial including women in the moderate-risk, high-risk and highest-risk groups for developing VTE after benign gynecologic surgery. Participants were randomized at a 1 : 1 ratio into parallel groups to receive either seven daily doses of 3500 IU of subcutaneous bemiparin or to a non-intervention group receiving standard rehydration and advice on ambulation. Participants were followed up for 7 days and 30 days postoperatively for symptomatic VTE, which was confirmed by compression Doppler ultrasound, magnetic resonance imaging, or computed tomographic pulmonary angiography, according to the type of VTE. Results: In total, 387 participants were randomized to the bemiparin group and 387 to the non-intervention group. The incidence of symptomatic VTE (deep vein thrombosis and pulmonary embolism) events was lower (0/377) in participants who received bemiparin than in those who received no pharmacologic intervention (12/380, 3.2%; 95% confidence interval [CI] 0.002-0.6). Logistic regression analysis showed significant associations between VTE and immobility (odds ratio [OR] 7.1; 95% CI 1.3-36.2), varicose veins (OR 16.8; 95% CI 3.1-76.2), and thrombophilia (OR 39.3; 95% CI 1.5-1006.7). There were no major bleeding events or side effects related to the use of bemiparin. Conclusions: Bemiparin was an effective thromboprophylactic agent for preventing venous thrombosis after benign gynecologic surgery.

show abstract

Section: Discussionsupporting

confidence: 92%

Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial

Alalaf

Jawad

et al. 2015

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Equivalent risk reductions were seen with the use of preoperative and daily postoperative low molecular weight heparin when compared with intermittent pneumatic compression devices (15). A retrospective analysis of more than 3,500 patients showed a statistically significant reduction in DVT and fatal pulmonary embolism in patients receiving low molecular weight heparin prophylaxis compared with those who did not, although the investigators did not control for use of mechanical methods (46). A retrospective analysis of more than 3,500 patients showed a statistically significant reduction in DVT and fatal pulmonary embolism in patients receiving low molecular weight heparin prophylaxis compared with those who did not, although the investigators did not control for use of mechanical methods (46).…”

Section: Low Molecular Weight Heparinmentioning

confidence: 99%

ACOG Practice Bulletin No. 84: Prevention of Deep Vein Thrombosis and Pulmonary Embolism

2007

Obstetrics &Amp; Gynecology

118

View full text Add to dashboard Cite

“…A major prospective trial of 2,373 patients demonstrated a 2% incidence of clinical venous thromboembolism in patients undergoing general, urologic, and gynecologic surgery for cancer who received low molecular weight heparin prophylaxis [2]. Finally, a retrospective analysis of more than 3,500 patients found a significant reduction in both deep vein thrombosis and pulmonary embolism in patients receiving low molecular weight heparin prophylaxis compared with those patients who did not [39]. …”

Section: Pharmacologic Prophylaxis Agentsmentioning

confidence: 99%

Prevention of venous thromboembolism in gynecologic oncology surgery

Barber

Clarke‐Pearson

2017

Gynecologic Oncology

View full text Add to dashboard Cite

Gynecologic oncology patients are at a high-risk of postoperative venous thromboembolism and these events are a source of major morbidity and mortality. Given the availability of prophylaxis regimens, a structured comprehensive plan for prophylaxis is necessary to care for this population. There are many prophylaxis strategies and pharmacologic agents available to the practicing gynecologic oncologist. Current venous thromboembolism prophylaxis strategies include mechanical prophylaxis, preoperative pharmacologic prophylaxis, postoperative pharmacologic prophylaxis and extended duration pharmacologic prophylaxis that the patient continues at home after hospital discharge. In this review, we will summarize the available pharmacologic prophylaxis agents and discuss currently used prophylaxis strategies. When available, evidence from the gynecologic oncology patient population will be highlighted.

show abstract

Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin

Cited by 10 publications

References 15 publications

Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial

Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial

ACOG Practice Bulletin No. 84: Prevention of Deep Vein Thrombosis and Pulmonary Embolism

Prevention of venous thromboembolism in gynecologic oncology surgery

Contact Info

Product

Resources

About